# Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Canonical URL: https://biopharmsignal.com/news/NERV/minerva-neurosciences-presents-data-from-its-open-label-safety-trial-evaluating-roluperidone-co-administered-with-olanzapine-at-sirs-2026
Ticker: NERV
Company: Minerva Neuroscience
Source: Minerva Neuroscience
Published: 2026-03-25 20:05 EST
Original Source URL: https://ir.minervaneurosciences.com
## Summary

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) --

## Article Body
Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) --
## Recent Company News
- 2026-06-01 20:05 EST — [Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs](https://biopharmsignal.com/news/NERV/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs) — Source: Minerva Neuroscience
- 2026-05-18 20:05 EST — [Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/NERV/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference) — Source: Minerva Neuroscience
- 2026-05-05 12:00 EST — [Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/NERV/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates) — Source: Minerva Neuroscience
- 2026-04-02 20:05 EST — [Minerva Announces Leadership Transition](https://biopharmsignal.com/news/NERV/minerva-announces-leadership-transition) — Source: Minerva Neuroscience
- 2026-03-31 20:05 EST — [Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia](https://biopharmsignal.com/news/NERV/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia) — Source: Minerva Neuroscience
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)